Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-&bgr;-1b treatment in relapsing remitting MS

Author： Goertsches Robert H   Hecker Michael   Koczan Dirk   Serrano-Fernandez Pablo   Moeller Steffen   Thiesen Hans-Juergen   Zettl Uwe K  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.11, Iss.2, 2010-02, pp. : 147-161

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

An Inventory of Short Term and Long Term Changes in Gene Expression Under Interferon β Treatment of Relapsing Remitting MS Patients

By  

Current Pharmaceutical Design, Vol. 18, Iss. 29, 2012-10 ,pp. : 4475-4484

Bentham Science Publishers

Access to resources Recommend Favorite

IFN- treatment cost driver in relapsing-remitting MS

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 458, 2004-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

IFN- treatment cost driver in relapsing-remitting MS

By  

Inpharma, Vol. 1, Iss. 1448, 2004-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Long-Term Cost Effectiveness of Interferon- -1a in the Treatment of Relapsing-Remitting Multiple Sclerosis: An Econometric Model

By Lepen C.  

Clinical Drug Investigation, Vol. 23, Iss. 9, 2003-01 ,pp. : 571-581

Adis International

Access to resources Recommend Favorite

Interferon- -1b good value for money in relapsing-remitting MS

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 317, 2001-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite